Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Non Operating Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Non Operating Income for 4 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 42.5% to $57000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$19000.0, a 101.56% decrease, with the full-year FY2025 number at -$19000.0, down 101.56% from a year prior.
  • Other Non Operating Income was $57000.0 for Q4 2025 at Day One Biopharmaceuticals, up from -$34000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.2 million in Q3 2024 to a low of -$34000.0 in Q3 2025.
  • A 4-year average of $76000.0 and a median of -$10000.0 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 300.0% in 2023, then surged 40000.0% in 2024.
  • Day One Biopharmaceuticals' Other Non Operating Income stood at -$26000.0 in 2022, then soared by 30.77% to -$18000.0 in 2023, then skyrocketed by 322.22% to $40000.0 in 2024, then soared by 42.5% to $57000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Other Non Operating Income are $57000.0 (Q4 2025), -$34000.0 (Q3 2025), and -$19000.0 (Q2 2025).